Sometimes a little perspective can be a marvelous thing...
apologies for the length of the post right at the start but some myths around these results and the companies work need to be addressed, ....investors will find it potentially interesting, speculators can please themselves.
Dronabinol ....one of the combinant drugs being used in IHLs' OSA drug is already approved by the FDA .
Not only that, but it has been established as treatment for OSA
already with a globally recognised 30% reduction in the triggering of / effects of sleep apnea. ....that 30% is verified in a study by Carley et al conducted in 2003. - it has been independently verified by 3 other studies globally to repeat the outcome and the same reduction was achieved/ evidenced in those same studies.
That 30% is already recognised as a major clinical breakthrough in the space.....yes globally reconised.....exactly why pharmacological studies and research continue in the area of this drug alone.
Investor take away from the above:
Dronabinol
already has the patient group study outcomes which indicate a 30% reduction in the effects of sleep apnea.....interestingly applicable to both peripheral sleep apnea 2018 Carley was involved in further pharmacological research which indicated cannabinoid co therapy with dronabinol enhanced the patient outcomes and removed the adverse side effects of the dronabinol revealed in the 2003 outcomes.
see link and snip
https://academic.oup.com/sleep/article/41/1/zsx184/4600041
So a lot of the speculation that appears to be critical of this study by IHL is unfounded due mainly to lack of research by holders and 'Mr Market' in the area around the pharmacological work that has already been completed in relation to Dronabinol and CBD -
Incannex recognised the opportunity of the previous work done in this field and the research and outcomes detailing the effectiveness and efficacy associated with the historical pharmacology around the synergistic potential and the possible drug candidate that could produce a medical treatment ....a drug that would further enhance the previous study work and capture a market where
no such treatment currently exists.this is the opportunity investors have to be aboard a company with this sort of scientific rigor and understanding of the market opportunity to develop and meet this unmet need......bye bye CPAP hello efficacious drug treatment candidate.
by the by ....50% of patients prescribed CPAP abandon it in the first 12 months.......think about that - this is the prescribed standard of care in the space that is designed to cure you of your affliction and it has a 50% drop out rate in the first year of use.
by any measure that is a fail of a treatment.
why is it the prescribed treatment? ...pretty good question
obviously
It is an oxygen supply feed line that is designed to provide O2 in abundance to treat the underlying condition of either peripheral and or central apnea hypopnea ....all i have to say i
s what a crock!
in any designed prescribed treatment where only the symptom of the affliction are a addressed as the root cause will see a failed outcome....that is common sense in anyone's book.
so it follows to ask then what is the cause of these apneic events in sufferers?
during sleep periods the brain / CNS fail to recognise increasing levels of carbon dioxide in the system so these levels rise, triggering an over breathing response to expel the rising levels of CO2 caused by under breathing....such that this event of triggered over breathing causes excessive blow off of CO2 resulting in the apneoic state ....'paused' breathing or apnea.....of course it triggers then the cycle to repeat itself in sufferers of the affliction.
a CPAP device only supplies oxygen when that triggered response occurs partially mitigating the extent of the carbon dioxide 'blow off'....it does not cure the condition within the brain/ CNS that is the condition itself.....hence the 50% drop out rate described above.....some evidence coming to the fore does suggest this (CPAP) contributes to these apneoic events but at a reduced severity ......again. by any measure that is not a successful treatment outcome. - so it remains a massive unmet market opportunity $$$$
( worth mentioning this affliction has multiple associated effects such as increased levels of coronary heart disease and stroke events...)
so....these study results by IHL is
their analysis of the preliminary data of the study multiple dose were designed and trialed in this study
my takeaway
60% of participants experienced a reduction in AHI of greater than 50% (range: 55.0% to 91.5%) and a resulting AHI of less than 20 during at least one treatment period of one dose strength of IHL-42X. 20% of participants experienced a reduction in AHI of greater than 80% (range: 82.7% to 91.5%) relative to baseline during at least one treatment period of one dose strength of IHL-42X.dose strength and outcome is yet to undergo analyses to determine optimum dose strength and outcomeIncannex await the specific data from the study to be supplied by Novotech
'This will include a comparison between IHL-42X doses for each patient, which increases the power of the analysis, and provides a more robust differentiation of dose strengths. The full clinical study report is anticipated in Q2 2022.'
and this release below refers specifically to the historical work described above in this post
'Preliminary analysis also revealed that IHL-42X was observed to be well tolerated in the clinical trial. All treatment associated adverse events were consistent with what has been reported for constituent components of IHL-42X in historic studies.'
look forward to that data in the full clinical study report
anticipated in Q2 2022
ill be ignoring the noise that has seemed to fill the thread these last few days ....it bears no relationship to the progression of the drug candidate IHL 42x as it begins to emerge
as the first drug medication with the potential to treat the billion dollar market opportunity that is OSA.by any standard - these preliminary findings are first in class ......that is beyond question as supported by the historical research identified globally.
is there further opportunity to progress this proprietary novel and inventive potential medication?
when you recognise that CBDA is in fact more beneficial than CBD in the area of efficacious endocannabinoid assimilation then yes......i believe this will be the natural progression in IHL 42X should this OSA work Incannex are undertaking be a success -
all indications are this will be the case -
